| Author/Editor | Stegel, Vida | |
| Title | Priprava in uporaba tumorskih cepiv iz mononuklearnih celic na eksperimentalnih tumorskih modelih | |
| Type | monografija | |
| Place | Ljubljana | |
| Publisher | Univerza v Ljubljani, Medicinska fakulteta | |
| Publication year | 2006 | |
| Volume | str. 126 | |
| Language | slo | |
| Abstract | Introduction. Conventional methods used for cancer treatment (surgical resection, chemotherapy, radiation) do not always destroy all tumor cells or stop the progress of disease. Lately, biological drugs are more and more used as adjuvant therapies. Among the biological drugs, tumor vaccines are of special importance. Tumor vaccines are predominantly based on in vivo stimulation of immune system, or on adoptive transfer of in vitro stimulated immune cells. Hypothesis. The hypothesis of this doctoral thesis is that immnnostimulators have a decisive impact on stimulation of mononuclear cells (MNC) in tumor vaccine preparation. Aim The aim of this study was to optimize the preparation of tumor vaccines based on in vitro and in vivo stimulation of MNC. Experiments were divided in three parts: (I ) in vitro direct and indirect stimulation of MNC with irradiated B16P1 tumor cells anti unspecific immunostimulators (MV6-2, BCG, CPG, KLH), (2) in vivo activation of antitumor immune response with irradiated B16F1 and immunostimulators (CpG and KLH) and (3) determination of some mechanism of action of irradiated B16F1 and inununostimulator. Material and Methods. MNC were stimulated with irradiated malignant melanoma tumor cells B16F1 and different immunostimulators (MVE-2, BCG, CpG, KLH). The level of in vitro activation of MNC was evaluated by measuring the proportion of activation markers CD25. CD69, IL4 and IFgamma on T lymphocytes using flow-cytometry as well as by determining cytotoxic activity. The in vivo activation of antitumor immune response induced by irradiated B16F1, CpG or KLH was evaluated by determining the tumor prevention and treatment effect in the aimals injected i.p. with B16F1 viable tumor cells. (Abstract truncated at 2000 characters) | |
| Descriptors | CANCER VACCINES TUMOR CELLS, CULTURED ADJUVANTS, IMMUNOLOGIC ANTIGENS, NEOPLASM DENDRITIC CELLS T-LYMPHOCYTES RECEPTORS, INTERLEUKIN-2 HLA-DR ANTIGENS INTERLEUKIN-4 INTERFERON TYPE II MELANOMA, EXPERIMENTAL MICE, INBRED C57BL |